FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to obtaining regulatory dendritic cells, and can be used in medicine for treating diseases due to immunological anomalies and excess immune responses. Method comprises differentiation into regulatory dendritic cells, which can be induced in order to obtain regulatory dendritic cells, in presence of (S)-(+)-1-(5-hydroxy-1,5-dimethylhexyl)-3-[7-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]urea, GM-CSF and IL-4 and subsequent ageing of regulatory dendritic cells in presence of TNF-α and/or LPS.
EFFECT: higher quality and longer period of survival of patients during transplantation of said regulatory dendritic cells.
10 cl, 2 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINE-2-YLUREA DERIVATIVE AND ITS APPLICATION | 2004 |
|
RU2348636C2 |
| METHOD FOR INDUCING IMMUNOLOGICAL TOLERANCE ON TRANSPLANTATION ANTIGENS IN MAMMALS | 2018 |
|
RU2717011C1 |
| COMPOSITION FOR PREVENTING OR TREATING MALIGNANT TUMOUR, COMPRISING AGENT DESTROYING VESSELS, AND IMMUNE CONTROL POINT INHIBITOR | 2018 |
|
RU2738369C1 |
| IMMUNOMODULATORY AGENT, CANCER AGENT AND HEALTHY FOOD CONTAINING MONOACETYLDIACYLGLYCERIN DERIVATIVES | 2005 |
|
RU2341257C2 |
| RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | 2018 |
|
RU2790447C2 |
| MODULAR PARTICLES FOR IMMUNOTHERAPY | 2014 |
|
RU2672055C2 |
| REPROGRAMMING HUMAN ENDOTHELIUM IN HEMATOPOIETIC PRECURSORS OF MULTIPLE LINES OF DIFFERENTIATION USING CERTAIN FACTORS | 2014 |
|
RU2691062C2 |
| METHODS OF TREATING AUTOIMMUNE DISEASES WITH DLL4 ANTAGONISTS | 2011 |
|
RU2587620C2 |
| MODIFIED DENDRITIC CELLS AND USE THEREOF IN TREATING MALIGNANT TUMOURS | 2017 |
|
RU2711606C2 |
| MODIFIED DENDRITIC CELLS AND THEIR APPLICATION FOR MALIGNANT TUMOURS TREATMENT | 2013 |
|
RU2644210C2 |
